ERCC1在以铂类药物为基础的非小细胞肺癌化疗中的研究进展

doi:10.3760/cma.j.issn.1673-422X.2014.12.010

摘要/Abstract

摘要： 核苷酸切除修复交叉互补组1（ERCC1）基因是DNA修复蛋白在核苷酸切除修复（NER）通路的限速酶，研究提示ERCC1参与非小细胞肺癌铂类化疗药物的耐药发生。因此，ERCC1基因作为目前恶性肿瘤基因治疗研究中的新靶点，为恶性肿瘤特别是非小细胞肺癌的治疗提供了新的思路。

关键词: 顺铂, 癌, 非小细胞肺, 核苷酸切除修复交叉互补组1

Abstract: Excision repair cross complementing group 1 (ERCC1) gene is an enzyme of the speed limit of DNA repair protein in nucleotide excision repair (NER) pathways.Researches suggest that ERCC1 has been associated with cisplatin resistance in nonsmall cell lung cancer (NSCLC) patients. Thus, ERCC1 gene is a new target in malignant tumor gene therapy research,providing a new approach for the treatment of malignant,especially NSCLC.

Key words: Cisplatin, Carcinoma, Nonsmall cell lung, Excision repair cross complementing group 1

柳志宝, 张菁华. ERCC1在以铂类药物为基础的非小细胞肺癌化疗中的研究进展[J]. 国际肿瘤学杂志, 2014, 41(12): 909-912.

LIU Zhi-Bao, ZHANG Jing-Hua. Research progress of ERCC1 in non-small cell lung cancer based on the platinum drugs[J]. Journal of International Oncology, 2014, 41(12): 909-912.

参考文献

［1］ Pignon J, Tribodet H, Scagliotti G, et al. Lung adjuvant cisplatin evaluation:a pooled analysis by the LACE Collaborative Group［J］. J Clin Oncol, 2008, 26(21): 35523559. ［2］ Bepler G, Olaussen K, Vataire A, et al. ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis［J］. Am J Pathol, 2011, 178(1): 6978. ［3］ De Dosso S, Zanellato E, Nucifora M, et al. ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatinbased chemotherapy［J］. Cancer Chemother Pharmacol, 2013, 72(1):159165. ［4］ Li Y, Yang SY, Kang S, et al. Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy［J］. Pharmacogenomics, 2012, 13(4): 419427. ［5］ Li P, Fang YJ, Li F, et al. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage Ⅲ colon cancer patients receiving oxaliplatinbased adjuvant chemotherapy［J］. Br J Cancer, 2013, 108(6): 12381244. ［6］ Gerhard R, Carvalho A, Carneiro V，et al. Clinicopathological significance of ERCC1 expression in breast cancer［J］. Pathol Res Pract, 2013, 209(6): 331336. ［7］ Krawczyk P, WojasKrawczyk K, Mlak R, et al. Predictive value of ERCC1 singlenucleotide polymorphism in patients receiving platinumbased chemotherapy for locallyadvanced and advanced nonsmall cell lung cancer—a pilot study［J］. Folia Histochem Cytobiol, 2012, 50(1): 8086. ［8］ Roth JA ,Carlson JJ. Prognostic role of ERCC1 in advanced nonsmallcell lung cancer: a systematic review and metaanalysis［J］. Clin Lung Cancer, 2011, 12(6): 393401. ［9］ Hubner RA, Riley RD, Billingham L, et al. Excision repair crosscomplementation group 1 (ERCC1) status and lung cancer outcomes: a metaanalysis of published studies and Recommendations［J］. PLoS One, 2011, 6(10): e25164. ［10］ Gregg SQ，Robinson AR，Niedernhofer LJ．Physiological consequences of defects in ERCC1XPF DNA repair endonuclease［J］．DNA Repair(Amst), 2011, 10(7): 781791．［11］ Orelli B, Mcclendon T, Tsodikov O, et al. The XPAbinding domain of ERCC1 is required for nucleotide excision repair but not other DNA repair pathways［J］. J Biol Chem, 2010, 285(6): 37053712. ［12］ Li J, Li Z, Yu LC, et al. Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced nonsmall cell lung cancer who received neoadjuvant chemotherapy［J］. Lung Cancer, 2010, 69(1): 116122. ［13］ TsedenIsh M, Choi YD, Cho HJ, et al. Diseasefree survival of patients after surgical resection of nonsmall cell lung carcinoma and correlation with excision repair crosscomplementation group 1 expression and genotype［J］. Respirology, 2012, 17(1): 127133. ［14］ Leng XF, Chen MW, Xian L, et al. Combined analysis of mRNA expression of ERCC1, BAG1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with nonsmall cell lung cancer who received adjuvant chemotherapy［J］. J Exp Clin Cancer Res, 2012, 31(25): 157162. ［15］ Wang X， Zhao J， Yang L， et al． Positive expression of ERCC1 predicts a poorer platinumbased treatment outcome in Chinese patient with advanced nonsmall cell lung cancer［J］．Med Oncol， 2010, 27(2): 484490．［16］ Yan D, Wei P, An G,et al.Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage Ⅲ（N2） nonsmall cell lung cancer［J］. J Cardiothorac Surg, 2013, 8(1): 149153. ［17］ Zhang S, Li Q, Zhang Q, et al. Expression of ERCC1 and class Ⅲ βtubulin in resected nonsmall cell lung cancer and its correlation with platinumbased adjuvant chemotherapy［J］. Int J Biol Markers, 2010, 25(3): 141149. ［18］ Usanova S, PiéeStaffa A, Sied U, et al. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrandcrosslink repair and low ERCC1XPF expression［J］. Mol Cancer, 2010, 9(3): 248260. ［19］ Ma D, Baruch D, Shu Y, et al. Using protein microarray technology to screen antiERCC1 monoclonal antibodies for specificity and applications in pathology［J］. BMC Biotechnol, 2012, 12(1): 88. ［20］ Jiang J, Liang X, Zhou X, et al. ERCC1 expression as a prognostic and predictive factor in patients with nonsmall cell lung cancer: a metaanalysis［J］. Mol Biol Rep, 2012, 39(6): 69336942. ［21］ Seyhan EC, Altin S, Cetinkaya E, et al. Prognostic significance of ERCC1 expression in resected nonsmall cell lung carcinoma［J］. Ann Thorac Cardiovasc Surg, 2011, 17(2): 110117. ［22］ Zhu XD, Niedernhofer L, Kuster B, et al. ERCC1/XPF removes the 3′overhang from uncapped telomeres and represses formation of telomeric DNAcontaining double minute chromosomes［J］. Mol Cell, 2003, 12(6): 14891498.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[3]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[4]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[5]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[6]	顾芳萌, 徐晨阳, 雷大鹏. 人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[7]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[8]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[9]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[10]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[11]	胡婷婷, 王越华. 电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[12]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[13]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[14]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[15]	钱晓涛, 石子宜, 胡格. Ⅲ~ⅣA期食管鳞状细胞癌根治性放化疗后行免疫检查点抑制剂维持治疗的真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(3): 151-156.